PDF(Pubmed)
Abstract：
UNASSIGNED: Neonatal seizures are common, but the impact of neonatal seizures on long-term neurologic outcome remains unclear. We addressed this question by analyzing data from an early-phase controlled trial of bumetanide to treat neonatal seizures.
UNASSIGNED: Neonatal seizure burden was calculated from continuous video-EEG data. Neurologic outcome was determined by standardized developmental tests and post-neonatal seizure recurrence.
UNASSIGNED: Of 111 enrolled neonates, 43 were randomized to treatment or control groups. There were no differences in neurologic outcome between treatment and control groups. A subgroup analysis was performed for 84 neonates with acute perinatal brain injury (57 HIE, 18 stroke, 9 ICH), most of whom (70%) had neonatal seizures. There was a significant negative correlation between seizure burden and developmental scores (p<0.01). Associations between seizure burden and developmental scores were stronger in HIE and stroke groups compared with ICH (p<0.05).
UNASSIGNED: Bumetanide showed no long-term beneficial or adverse effects, as expected based on treatment duration versus duration of neonatal seizures. For neonates with perinatal brain injury, higher neonatal seizure burden correlated significantly with worse developmental outcome, particularly for ischemic versus hemorrhagic brain injury. These data highlight the need for further investigation of the long-term effects of both neonatal seizure severity and etiology.
UNASSIGNED: Neonatal seizure burden was calculated from continuous video-EEG data. Neurologic outcome was determined by standardized developmental tests and post-neonatal seizure recurrence.
UNASSIGNED: Of 111 enrolled neonates, 43 were randomized to treatment or control groups. There were no differences in neurologic outcome between treatment and control groups. A subgroup analysis was performed for 84 neonates with acute perinatal brain injury (57 HIE, 18 stroke, 9 ICH), most of whom (70%) had neonatal seizures. There was a significant negative correlation between seizure burden and developmental scores (p<0.01). Associations between seizure burden and developmental scores were stronger in HIE and stroke groups compared with ICH (p<0.05).
UNASSIGNED: Bumetanide showed no long-term beneficial or adverse effects, as expected based on treatment duration versus duration of neonatal seizures. For neonates with perinatal brain injury, higher neonatal seizure burden correlated significantly with worse developmental outcome, particularly for ischemic versus hemorrhagic brain injury. These data highlight the need for further investigation of the long-term effects of both neonatal seizure severity and etiology.
摘要：
■新生儿癫痫发作很常见，但新生儿惊厥对长期神经系统结局的影响尚不清楚.我们通过分析来自布美他尼治疗新生儿癫痫的早期对照试验的数据来解决这个问题。
■根据连续视频脑电图数据计算新生儿癫痫发作负担。通过标准化发育测试和新生儿癫痫发作后复发确定神经系统结局。
■在111名登记的新生儿中，43例随机分为治疗组或对照组。治疗组和对照组之间的神经系统结局没有差异。对84例急性围产期脑损伤新生儿进行亚组分析（57例HIE，18冲程，9ICH)，其中大多数（70％）患有新生儿癫痫发作。癫痫发作负担与发育评分呈显著负相关(p<0.01)。与ICH相比，HIE和卒中组的癫痫发作负担与发育评分之间的关联更强（p<0.05）。
■布美他尼没有长期的有益或不良反应，根据治疗持续时间与新生儿癫痫发作持续时间预期。对于围产期脑损伤的新生儿，较高的新生儿癫痫发作负担与较差的发育结局显着相关，特别是缺血性和出血性脑损伤。这些数据突出了需要进一步研究新生儿癫痫发作严重程度和病因的长期影响。
■根据连续视频脑电图数据计算新生儿癫痫发作负担。通过标准化发育测试和新生儿癫痫发作后复发确定神经系统结局。
■在111名登记的新生儿中，43例随机分为治疗组或对照组。治疗组和对照组之间的神经系统结局没有差异。对84例急性围产期脑损伤新生儿进行亚组分析（57例HIE，18冲程，9ICH)，其中大多数（70％）患有新生儿癫痫发作。癫痫发作负担与发育评分呈显著负相关(p<0.01)。与ICH相比，HIE和卒中组的癫痫发作负担与发育评分之间的关联更强（p<0.05）。
■布美他尼没有长期的有益或不良反应，根据治疗持续时间与新生儿癫痫发作持续时间预期。对于围产期脑损伤的新生儿，较高的新生儿癫痫发作负担与较差的发育结局显着相关，特别是缺血性和出血性脑损伤。这些数据突出了需要进一步研究新生儿癫痫发作严重程度和病因的长期影响。
